Hydralazine 50mg Extended-Release Tablets from Canada
Extended-release tablets providing 50mg hydralazine for once-daily dosing in managing chronic hypertension. Falls under HTS 3004.90.92.20 as a mixed product in measured doses for therapeutic cardiovascular use, put up for retail sale.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Verify extended-release mechanism compliance with FDA dissolution testing standards
• Provide detailed formulation specs including excipients to avoid reclassification as bulk chemical